2021
DOI: 10.3748/wjg.v27.i17.1847
|View full text |Cite
|
Sign up to set email alerts
|

Pancreatic adenocarcinoma: Beyond first line, where are we?

Abstract: Pancreatic cancer is considered one of the most aggressive cancers, with an increasing incidence in recent years. To date, chemotherapy is still the standard of care for advanced metastatic disease, unfortunately providing only a slight advantage in terms of survival. The molecular and cellular characteristics of pancreatic cancer cells, as well as the cells that characterize the pancreatic tumour microenvironment, are the basis of the mechanisms of resistance to treatment. After progression during first-line … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
5
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 8 publications
(5 citation statements)
references
References 90 publications
0
5
0
Order By: Relevance
“…After progression under GEM-based CT in first line, oxaliplatin, folinic acid and leucovorin (FA) and 5-FU (OFF) vs. FA and 5-FU alone (FF) were tested in a German phase III study including 168 patients. The median OS in the OFF group was significantly increased compared with the FF group (5.9 vs. 3.3 months; P=0.010) ( 103 , 104 ). The rates of adverse effects (AEs) were similar between groups.…”
Section: Options In the Treatment Of Metastatic Diseasementioning
confidence: 95%
“…After progression under GEM-based CT in first line, oxaliplatin, folinic acid and leucovorin (FA) and 5-FU (OFF) vs. FA and 5-FU alone (FF) were tested in a German phase III study including 168 patients. The median OS in the OFF group was significantly increased compared with the FF group (5.9 vs. 3.3 months; P=0.010) ( 103 , 104 ). The rates of adverse effects (AEs) were similar between groups.…”
Section: Options In the Treatment Of Metastatic Diseasementioning
confidence: 95%
“…PDAC was a very aggressive cancer which rapidly induced metastasis associated to the poor prognosis of this cancer ( 79 ). Only 20% of PDAC were surgically resectable often associated to neo-adjuvant treatment ( 83 ). However, the level of relapse was particularly high (>70%).…”
Section: Anti-tumoral Properties Of Orexins and Receptor Antagonist A...mentioning
confidence: 99%
“…Pancreatic ductal adenocarcinoma (PDAC), which represents over 90% of pancreatic exocrine cancers, is one of the most lethal cancers, with a 5-year survival rate of about 10% [ 40 , 41 ]. Other rare pancreatic exocrine cancers are adenosquamous carcinoma, squamous cell carcinoma and intraductal papillary mucinous neoplasms (IPMN) including colloid carcinoma [ 42 ]. According to projections, PDAC could represent the second largest cause of cancer-related deaths in 2030 [ 43 ].…”
Section: Orexins and Digestive Cancersmentioning
confidence: 99%
“…The poor prognosis of PDAC was related to the late stage of diagnosis involving systemic metastasis for over 50% of patients. About 20% of PDAC can be surgically resectable [ 42 ], frequently associated with neoadjuvant treatment. Unfortunately, the incidence of relapse remained high (over 75%) needing chemotherapy.…”
Section: Orexins and Digestive Cancersmentioning
confidence: 99%
See 1 more Smart Citation